Immune biomarkers, including programmed death 1 (PD-1) and its ligand (PD-L1), tumor mutational burden (TMB), and novel checkpoint targets, inform patient selection for immunotherapy and combination strategies. This evidence concerns the gene CD274 and neoplasm.